Nothing has changed for me... I continue to purchase additional shares (when I have some extra cash) at this reduced price. I see only positive catalysts in the future (DoD, increasing formulary approvals, Niyad sales, DSUVEO sales in the EU, Aguettant pre-filled syringe FDA approval in the US, etc.). The critical metric is sales. The lack thereof is what I believe is driving the plunge in stock price. 80% of analysts believe ACRX is a BUY. The others are NEUTRAL. Avg price target is $4.00/share which at the current .20c/sh is 2000% upside.
All the best
"ACRX is my TSLA"